U.S. Markets closed

Stereotaxis higher after CEO says incoming orders accelerating

Stereotaxis (STXS), which develops robotic surgery tools, is rallying today after the company made some optimistic comments at Oppenheimer's Healthcare Conference yesterday afternoon. The company is seeing an acceleration in incoming orders which it believes will lead to "stronger financials in the future," said Stereotaxis' CEO Mike Kaminski. The response to Sterotaxis' new Vdrive, which enables surgeons to remotely manipulate catheters has been "exceptionally strong," the CEO said. The company estimates that 50% of its customers will upgrade to the new system this year and the product has triggered increased interest in buying new systems from Sterotaxis, Kaminski commented. Sterotaxis expects Vdrive to be launched in the U.S. in 2013, he added. Meanwhile, the company believes that it can expand to more geographic markets through additional partnerships, the CEO noted. In mid-morning trading, Stereotaxis jumped 70c, or 35%, to $2.70.